Abcuro
1 follower
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class ant... Read more
Org chart
Alex Martin
CEO
Alex Martin
Collapse
H. Jeffrey Wilkins, MD
Chief Medical Officer
Ricky Motschwiller
Controller
Dulce Soler-Ferran
VP, Biology
Janaki Subramanyam
VP, Head of Regulatory Affairs
Dave Borbas
Research VP, Head of Data Management
Garry Weems
VP, Clinical Science
Mike Gress
VP, Clinical Development & Head, Clinical Trial Management
Daniel Mansuri
Head, Corporate Development
Kristin Lurk
Senior Director, Program Management
LaDonna Hoffer
Senior Director, Operations
Hugo Lemessurier
Director
Donna Byrne
Director, Clinical Operations
Raquel Orozco
Director, CMC Manufacturing Operations
Terry Chaney
Associate Director, GMP QA Operations
Bill Yates
VP, Information Technology
Chidi Obi
Director, Analytical Development
Karma Tashi
Director, GMP Quality Drug Substance
Jeffrey Luk
Director & Head, Manufacturing
Jeff Geary
Director, Human Resources
Andrew Marth
Director, Quality Control
Zarna Patel
Director, Quality Systems
Weilee Chen
Senior Manager, CMC Downstream Manufacturing
Eileen Brennan
Senior Manager, Regulatory Affairs
Stephanie Amador
Senior Manager, CMC Project Management
